2 not yet recruiting, 2 recruiting, 1 active not recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Ivonescimab: new trials by email Literature Review of Ivonescimab trials Research Report on Ivonescimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) Ivonescimab, IP PTX - Phase II, Ivonescimab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-01-16 | 2026-08-27 |
| A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC AK112, AK112 + Neoadjuvant chemotherapy - Esophageal Squamous Cell Carcinoma, Ivonescimab | Phase 1 / Phase 2 | Recruiting | Tang-Du Hospital | 45 | 2026-01-28 | 2026-02-03 |
| Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） - HNSCC, OSCC | Active not recruiting | Zhujiang Hospital | 20 | 2026-01-26 | 2026-10-27 | |
| AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer AK112, FOLFIRI, Bevacizumab - Colorectal Cancer, Ivonescimab | Phase 2 | Not yet recruiting | Sun Yat-sen University | 130 | 2025-08-10 | 2025-06-15 |
| Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma Ivonescimab - Ivonescimab, Clear Cell Renal Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2025-07-02 | 2026-08-20 |
Adenocarcinoma, Mucinous (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (5) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (2) · Carcinoma, Squamous Cell (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2) · Colonic Diseases (1) · Esophageal Diseases (1) · Esophageal Neoplasms (1)
Bevacizumab (1) · IFL protocol (1) · Neoadjuvant Therapy (1)
M.D. Anderson Cancer Center (2) · Sun Yat-sen University (1) · Tang-Du Hospital (1) · Zhujiang Hospital (1)
China (2) · United States (2)
Beth Helmink, MD (1) · Pavlos Msaouel, MD (1) · Ruihua Xu, MD, PhD (1)